

Pfizer Inc  
Worldwide Regulatory Affairs and Quality Assurance  
50 Pequot Avenue  
New London, Connecticut 06320



---

## Global Research & Development

December 13, 2004

Dockets management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane, rm. 1061  
Rockville, Maryland 20852

Re: ICH Draft Guidance on S7BB Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals  
[Docket No. 2004D-0378, 69 *Federal Register*, 55164-55165, September 13, 2004]

Dear Dockets Management:

Pfizer Inc submits these comments on the ICH Draft Guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals published in the *Federal Register* on September 13, 2004. Pfizer discovers, develops, manufactures, and markets leading prescription medicines for humans and animals. Our innovative, value-added products improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives.

Our comments are attached.

We thank you for this opportunity to comment and would invite direct dialogue with the Agency if you would consider the opportunity valuable.

Sincerely,

A handwritten signature in black ink that reads "William R. Murphy". The signature is written in a cursive style.

William R. Murphy  
Director  
Pfizer Global Research and Development